文献速递胸部肿瘤

转移性HER2突变肺癌的最佳全身治疗及ctDNA在真实世界中的临床应用

Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer.
PubMed 文献 · Eur J Cancer · 2024-08-14

该回顾性研究分析了2016年1月至2022年9月在纪念斯隆-凯特琳癌症中心接受ctDNA测序和全身治疗的63例转移性HER2突变非小细胞肺癌患者,发现化疗免疫治疗仍是主要一线选择,中位至下次治疗时间5.1个月,而基线可检测ctDNA与更短总生存显著相关(HR 5.25)。

要点

  • 化疗免疫治疗为最常见一线方案,中位至下次治疗时间5.1个月(95%CI 4.1-6.1)。
  • 二线T-DXd中55.0%(22/40)患者获得中位至下次治疗时间9.2个月(95%CI 0-22.2)。
  • 基线可检测ctDNA患者总生存显著更短(HR 5.25,95%CI 1.2-23.9,p=0.019)。

核心结论

  • 化疗免疫治疗仍是转移性HER2突变非小细胞肺癌的主要治疗选择。
  • ctDNA可快速检测HER2突变及共突变,有潜力指导和监测最佳一线治疗。
  • 基线可检测ctDNA是负向预后生物标志物,未来研究选择患者时需加以考虑。

研究设计与样本

  • 回顾性分析2016年1月至2022年9月在纪念斯隆-凯特琳癌症中心接受前瞻性临床ctDNA测序并接受全身治疗的转移性HER2突变非小细胞肺癌患者。
  • HER2突变通过MSK-IMPACT、MSK-ACCESS或Resolution ctDx LungTM assay二代测序鉴定。
  • 主要终点为至下次治疗时间和总生存,主要分析纳入63例患者。

主要发现

  • 化疗免疫治疗为最主要一线治疗(33/63,52.4%),中位至下次治疗时间5.1个月(95%CI 4.1-6.1)。
  • 接受二线T-DXd的患者中55.0%(22/40)获得中位至下次治疗时间9.2个月(95%CI 0-22.2)。
  • 40例患者在一线治疗前接受血浆ctDNA检测,中位总生存28.0个月(95%CI 21-34),其中31例(78.0%)可检测到ctDNA。
  • ctDNA检测HER2突变的中位周转时间为13天,偶见与EGFR和MET变异共发生,并可纵向追踪与治疗反应相关。
  • 基线可检测ctDNA患者总生存显著更短(HR 5.25,95%CI 1.2-23.9,p=0.019)。

关键数值与推荐

  • HER2突变通过MSK-IMPACT、MSK-ACCESS或Resolution ctDx LungTM assay二代测序鉴定。
  • 主要终点为至下次治疗时间和总生存。
  • 基线可检测ctDNA患者总生存显著更短(HR 5.25,95%CI 1.2-23.9,p=0.019)。

临床怎么用

  • 化疗免疫治疗仍是转移性HER2突变非小细胞肺癌的主要治疗选择。
  • ctDNA可快速检测HER2及共突变,有潜力指导和监测最佳一线治疗。
  • 基线可检测ctDNA作为负向预后生物标志物,未来研究选择患者时需加以考虑。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: No definitive answers currently exist regarding optimal first-line therapy for HER2-mutant NSCLC. Access to rapid tissue sequencing is a major barrier to precision drug development in the first-line setting. ctDNA analysis has the potential to overcome these obstacles and guide treatment. METHODS: We retrospectively analyzed patients with metastatic HER2-mutant NSCLC who underwent prospective clinical ctDNA sequencing and received systemic therapy at Memorial Sloan Kettering Cancer Center (MSK) from January 2016 to September 2022. HER2 mutations were identified by next-generation sequencing through MSK-IMPACT, MSK-ACCESS or Resolution ctDx LungTM assay. Primary endpoints were time to the next treatment (TTNT) and overall survival (OS). RESULTS: Sixty-three patients were included in the primary analysis. Chemoimmunotherapy (33/63, 52.4 %) was the predominant first-line treatment with a median TTNT of 5.1 months (95 %CI 4.1 - 6.1) whereas 55.0 % (22/40) of patients who received second-line T-DXd obtained a median TTNT of 9.2 m (95 % CI, 0-22.2). Plasma ctDNA was tested before first-line therapy in 40 patients with a median OS of 28.0 months (95 % CI 21-34), in whom 31 patients (78.0 %) had detectable ctDNA. HER2 mutations were detected on ctDNA with a median turnaround time of 13 days, occasionally co-occurred with EGFR and MET alterations and were tracked longitudinally correlating with treatment response. Patients with detectable baseline ctDNA had significantly shorter OS (hazard ratio (HR), 5.25; 95 % CI, 1.2-23.9; p = 0.019). CONCLUSION: Chemoimmunotherapy remains a major treatment option for metastatic HER2-mutant NSCLC. ctDNA can rapidly detect HER2 and co-mutations, and it has the potential to guide and monitor optimal first-line therapy. As a negative prognostic biomarker, detectable ctDNA at baseline would need to be taken into account for patient selection in future studies.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Liu SY, Erazo T, Jee J, et al. Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer. Eur J Cancer. 2024. PMID: 39151324. doi:10.1016/j.ejca.2024.114257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。